At the start of the trial, you are included because you have asymptomatic anal LGV infection. LGV means lymphogranuloma venereum, a type of infection caused by Chlamydia trachomatis.

Your treatment begins with doxycycline taken by mouth. The medicine is doxycycline monohydrate in 100 mg tablets.

You take 200 mg of doxycycline once daily for 7 days.

This means you take two 100 mg tablets by mouth each day for the full 7-day treatment course.

During the treatment period, you use a diary to record how well you take the medicine as instructed.

This record is used to check adherence, which means whether you took the medicine as planned.

At 4 weeks after treatment initiation, you have a follow-up assessment.

A sample from the anal area is collected again to check whether the infection is still present.

The main result is called microbiological cure. This means the test on the anal sample is negative for LGV at 4 weeks after treatment started.

The study also compares the sample from the start of the trial with the sample taken at 4 weeks to assess whether the infection has cleared, returned, or changed.

The anal samples collected at the start of the trial and at 4 weeks are tested in the laboratory.

The type of Chlamydia trachomatis present may be studied by checking a gene called ompA. This helps identify the strain, which is a specific form of the bacteria.

The amount of bacteria is also measured at the start and at 4 weeks using a laboratory test that counts DNA copies per microliter.

The study also checks for possible doxycycline resistance, which means whether the bacteria show signs of being less affected by the medicine.

Any adverse events are recorded during the trial. An adverse event is any unwanted health problem that happens during the study.

Any serious adverse events are also recorded. These are more severe health problems that require special attention.